This study confirms and extends these findings by demonstrating that, among participants with type 2 diabetes and established CVD or at high cardiovascular risk participating in the CANVAS trial, TNFR-1, TNFR-2 and KIM-1 predict adverse kidney outcomes. The gene discussed is TNFRSF1A; the disease is type 2 diabetes mellitus.